Revolution Medicines Inc.

11/05/2024 | Press release | Distributed by Public on 11/05/2024 15:22

Statement of Changes in Beneficial Ownership - Form 4

Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
GOLDSMITH MARK A
2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [RVMD] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
See Remarks
(Last) (First) (Middle)
C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE 		3. Date of Earliest Transaction (Month/Day/Year)
11/01/2024
(Street)
REDWOOD CITY, CA 94063 		4. If Amendment, Date Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) 		7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/01/2024 M(1) 9,100 A $4.09 309,270(2) D
Common Stock 11/01/2024 S(1) 9,100 D $55.0235(3) 300,170(2) D
Common Stock 11/01/2024 S(1) 5,000 D $55.0268(4) 20,424 I Trust(5)
Common Stock 11/01/2024 S(1) 5,000 D $55.0209(4) 20,424 I Trust(6)
Common Stock 465,604 I Trust(7)
Common Stock 11/04/2024 M(1) 50,900 A $4.09 351,070(2) D
Common Stock 11/04/2024 S(1) 50,900 D $55.5564(8) 300,170(2) D
Common Stock 11/04/2024 M(1) 36,600 A $0.49 336,770(2) D
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5) 		6. Date Exercisable and Expiration Date
(Month/Day/Year) 		7. Title and Amount of Underlying Securities
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4) 		10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4) 		11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $4.09 11/01/2024 M(1) 9,100 03/13/2023 03/12/2029 Common Stock 9,100 $ 0 232,129 D
Stock Option (Right to Buy) $4.09 11/04/2024 M(1) 50,900 03/13/2023 03/12/2029 Common Stock 50,900 $ 0 181,229 D
Stock Option (Right to Buy) $0.49 11/04/2024 M(1) 36,600 12/01/2020 03/20/2027 Common Stock 36,600 $ 0 30,846 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
GOLDSMITH MARK A
C/O REVOLUTION MEDICINES, INC.
700 SAGINAW DRIVE
REDWOOD CITY, CA 94063 		X See Remarks

Signatures

/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith 11/05/2024
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023.
(2) Includes 188,750 restricted stock units.
(3) This transaction was executed in multiple trades in prices ranging from $55.00 to $55.17, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
(4) This transaction was executed in multiple trades in prices ranging from $55.00 to $55.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
(5) Held by Jonathan Goldsmith Revocable Trust.
(6) Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.
(7) Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
(8) This transaction was executed in multiple trades in prices ranging from $55.00 to $55.87, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:
President and Chief Executive Officer
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.